Algorae Puts AI Drug Predictions to Third Lab Test on 40 Cancer Combinations [VIDEO]

Algorae's Peter Mac AI partnership enters a third phase, putting 40 AI-predicted drug combinations to the test across four cancer cell lines with results due within six months.

By Josua Ferreira -

Key Takeaways

  • Algorae will screen 40 AI-predicted drug combinations across four cancer cell lines at Peter Mac, with the full dataset due within six months.
  • The multi-anchor program narrowed over 9 million potential combinations to 40 candidates after commercial and intellectual property analysis.
  • A $49,109 competitive voucher, won in a round where 13 of 28 applicants were funded, supports the experimental work.
  • Earlier Peter Mac work found AOS2 identified synergistic combinations at about 2.5 times the rate of its predecessor.
  • The screens are preclinical with no efficacy outcomes reported, and no further work with Peter Mac has been agreed or funded.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher